Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Piotrowski, Katja ^b   Becker, Melanie ^b   Zugwurst, Julia ^b   Biller Friedmann, Ingeborg ^b   Spoettl, Gerald ^b   Greif, Martin ^b   Leber, Alexander W ^b   Becker, Alexander ^b   Laubender, Rüdiger P ^b   Lebherz, Corinna ^a   Goeke, Burkhard ^b   Marx, Nikolaus ^a   Parhofer, Klaus G ^b   Lehrke, Michael ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atherosclerosis; Coronary CT angiography; GLP 1

Indexed keywords

C REACTIVE PROTEIN; GLUCAGON LIKE PEPTIDE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SMOKING; THORAX PAIN;

AGED; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; PLAQUE, ATHEROSCLEROTIC; SEVERITY OF ILLNESS INDEX;

EID: 84881527658     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-117     Document Type: Article

References (24)

1. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364(9):829-841.
2. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002, 25(7):1135-1141. 10.2337/diacare.25.7.1135, 12087010.
3. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011, 343:d4169. 10.1136/bmj.d4169, 3144314, 21791495.
4. Lehrke M, Marx N. Cardiovascular effects of incretin-based therapies. Rev Diabet Stud 2011, 8(3):382-391. 10.1900/RDS.2011.8.382, 3280672, 22262075.
5. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132(6):2131-2157. 10.1053/j.gastro.2007.03.054, 17498508.
6. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50(3):609-613. 10.2337/diabetes.50.3.609, 11246881.
7. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence?. Gut 1996, 38(6):916-919. 10.1136/gut.38.6.916, 1383202, 8984033.
8. Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)-evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 1996, 135(4):425-432. 10.1530/eje.0.1350425, 8921824.
9. Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, Vilsboll T, Knop FK. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 2013, 56(5):965-972. Epub 2013 Feb 3, 10.1007/s00125-013-2841-0, 3687347, 23377698.
10. Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T, Izumi T. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol 2010, 9:17. 10.1186/1475-2840-9-17, 2891690, 20470376.
11. Broedl UC, Lebherz C, Lehrke M, Stark R, Greif M, Becker A, von Ziegler F, Tittus J, Reiser M, Becker C, et al. Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques. PLoS One 2009, 4(3):e4733. 10.1371/journal.pone.0004733, 2649379, 19266101.
12. Monami M, Cremasco F, Lamanna C, Colombi C, Desideri CM, Iacomelli I, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011, 2011:215764. 3092497, 21584276.
13. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013, 15(2):112-120. 10.1111/dom.12000, 22925682.
14. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011, 124(21):2338-2349. 10.1161/CIRCULATIONAHA.111.041418, 22007077.
15. Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, et al. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol 2012, 11:107. 10.1186/1475-2840-11-107, 3459720, 22973968.
16. Li CJ, Li J, Zhang QM, Lv L, Chen R, Lv CF, Yu P, Yu DM. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovasc Diabetol 2012, 11:142. 10.1186/1475-2840-11-142, 3533748, 23153177.
17. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol 2012, 11:64. 10.1186/1475-2840-11-64, 3434036, 22681705.
18. Gupta NA, Kolachala VL, Jiang R, Abramowsky C, Romero R, Fifadara N, Anania F, Knechtle S, Kirk A. The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. Am J Pathol 2012, 181(5):1693-1701. 10.1016/j.ajpath.2012.07.015, 22960075.
19. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, Eppler E, Bouzakri K, Wueest S, Muller YD, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011, 17(11):1481-1489. 10.1038/nm.2513, 22037645.
20. Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, Smith JP, Milionis HJ, Douglas KM, Nightingale P, Kitas GD. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009, 204(1):178-183. 10.1016/j.atherosclerosis.2008.08.036, 18848327.
21. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004, 53(3):654-662. 10.2337/diabetes.53.3.654, 14988249.
22. Orskov C, Andreasen J, Holst JJ. All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab 1992, 74(2):379-384. 10.1210/jc.74.2.379, 1730817.
23. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009, 94(6):1843-1852. 10.1210/jc.2008-1296, 2690432, 19336511.
24. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298(3):309-316. 10.1001/jama.298.3.309, 17635891.